Induction Chemotherapy Followed by Chemoradiation in Locally Advanced Pancreatic Cancer: an Effective and Well-tolerated Treatment

Clinical Oncology

Volumn 22, Issue 1, 2010, Pages 27-35

  Hudson, E ^a   Hurt, C ^b   Mort, D ^a   Brewster, A E ^a   Iqbal, N ^a   Joseph, G ^a   Crosby, T D L ^a   Mukherjee, S ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Chemoradiation; chemotherapy; locally advanced; pancreatic cancer

Indexed keywords

CAPECITABINE; GEMCITABINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73249145786     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.09.024     Document Type: Article

References (32)

1. Cancer Research UK. Cancer statistics. Available from:. http://info.cancerresearchuk.org/cancerstats/
2. Mukherjee S., Hudson E., Reza S., et al. Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer (LANPC). Clin Oncol (R Coll Radiol) 20 7 (2008) 535-540
3. Jackson A., and The pancreatic subgroup of ACCORN. Survey of current UK practice of pancreatic cancer management by clinical oncologists. Proceedings of combined chemo-radiotherapy for GI cancer (2007), BIR, London
4. Huguet F., Girard N., Guerche C.S., et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27 (2009) 2269-2277
5. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 9 (2008) 1592-1599
6. Sultana A., Tudur S.C., Cunningham D., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96 (2007) 1183-1190
7. Neoptolemos J.P., Stocken D.D., Friess H., et al. European Study Group for Pancreatic cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
8. Available from:. http://www.ncrn.org.uk/
9. Loehrer P.J., Powell M.E., Cardenes H.R., et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 26 Suppl. (2008) abstract 4506
10. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25 (2007) 326-331
11. Brade A., Brierley J., Oza A., et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 67 4 (2007) 1027-1036
12. Ko A.H., Quivey J.M., Venook A.P., et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68 3 (2007) 809-816
13. Reni M., Cereda S., Balzano G., et al. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2009 Nov64(6)) 1253-9.
14. Kachnic L.A., Shaw J.E., Manning M.A., et al. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int J Cancer 96 (2001) 132-139
15. Spry N., Harvey J., Macleod C., et al. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. Int J Radiat Oncol Biol Phys 70 5 (2008) 1438-1446
16. Krishnan S., Rana V., Janjan N.A., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110 1 (2007) 47-55
17. Huguet F., Andre T., Hammel P., et al. Chemoradiotherapy (CRT) after chemotherapy (CT) improves survival for locally-advanced (LA) pancreatic cancer patients: retrospective analysis of 181 patients enrolled in prospective phases II and III GERCOR studies. J Clin Oncol 23 16S (2005) 4095
18. Wilkowski R., Thoma M., Weingandt H., Dühmke E., and Heinemann V. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. JOP 6 2 (2005) 216-230
19. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
20. Cunningham D., Chau I., Stoken D., et al., NCRI Upper Gastrointestinal Cancer Clinical Study Group. Phase III randomized comparison of gemcitabine (GEM) vs gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Proc ECCO 13 (2005)
21. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25 (2007) 2212-2217
22. [No authors listed]. Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer. Cancer Biol Ther 6 2 (2007) 130
23. Philip P.A., Benedetti J., Fenoglio-Preiser C., et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25 18S (2007) LBA4509
24. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 15 (2007) 1960-1966
25. Milano M.T., Chmura S.J., Garofalo M.D., et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59 (2004) 445-453
26. Ben-Joseph E., Shields A.F., Vaishampayan U., et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59 (2004) 454-459
27. Wilkowski R., Thoma M., Schauer T., Wagner A., and Heinemann V. Effects of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 28 (2004) 1011-1018
28. Gastrointestinal Tumour Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755
29. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53 1 (2002) 146-150
30. Cardenes H.R., Powell M., Loehrer P.J., et al. E4201: randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): quality-of-life (QOL) analysis. J Clin Oncol 27 15s (2009) abstract 4627
31. Henry A., Ryder W., Moore C., et al. Chemoradiotherapy for locally advanced pancreatic cancer: a radiotherapy dose escalation and organ motion study. Clin Oncol 20 7 (2008) 541-547
32. Murphy J.D., Adusumilli S., Griffith K.A., et al. Full dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68 3 (2007) 801-808